Biomarker Insights from KRAS P.G12C-Mutated Subjects Treated with Sotorasib in Codebreak 100

Time: 9:30 am
day: Day One


  • Baseline biomarker subgroup associations with response in NSCLC subjects
  • 2-year follow-up assessing biomarker correlates for NSCLC subjects deriving long-term benefit from sotorasib treatment
  • Analysis of acquired mutations NSCLC and CRC to treatment to inform rational combo therapy